Obesity is explicitly listed as a Phase 1 program in public disclosures and is not a primary commercial focus for the drug
Authors: Karen G Farrar University of Southern California , Los Angeles, CA, Duy Do Truveta, Inc , Bellevue, WA, Nina B Masters Truveta, Inc , Bellevue, WA, Brianna M Cartwright Truveta, Inc , Bellevue, WA After CVS Caremark made anti-obesity semaglutide the preferred formulary option in July 2025, switching from anti-obesity tirzepatide surged from 0.6% to 9.7%, representing more than a 16-fold rise
These findings confirm that Retatrutide activates coordinated lipid oxidative programs at the pathway level, further supporting its capacity to remodel white adipose tissue toward a metabolically oxidative and energy-dissipating phenotype (Fig
An analysis of health insurance claims released Tuesday found that most people using GLP-1 medications about 58% were on their treatment plan for less than 12 weeks, falling short of a key benchmark in the weight-loss treatment timeline
However, a salient issue that patients face is preventing weight regain after the medication is discontinued
Is anyone getting Medicaid coverage of GLP-1 meds for antipsychotic induced weight gain
